Suzhou‑based AccurEdit Therapeutics closed a $75 million Series A to advance a pipeline of CRISPR‑based in vivo and ex vivo gene‑editing candidates. The round ranks among the larger early‑stage gene‑editing financings in China and will fund IND‑enabling studies and platform expansion to support therapeutic programs across indications. AccurEdit’s financing highlights sustained investor appetite for genome‑editing platforms despite regulatory and technical hurdles. The company plans to use proceeds to scale delivery systems, advance lead programs, and expand preclinical work toward first‑in‑human trials.